# OnCo record idea-bio2-lymph-node-immune-priming (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-bio2-lymph-node-immune-priming/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-bio2-lymph-node-immune-priming" ;
  schema:name "Treat the draining lymph node before removing it"@en ;
  schema:description "The first lymph node cancer reaches is also where the immune system learns to fight it. Injecting immunotherapy into that node before surgery, instead of removing it blindly, may work better."@en ;
  schema:url <https://onco.cc/ideas/idea-bio2-lymph-node-immune-priming/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1002/cam4.2474> ;
  onco:cancers <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/melanoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/sentinel-node/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/> ;
  onco:terms <https://onco.cc/terms/major-pathological-response/>, <https://onco.cc/terms/irae/> ;
  onco:trials <https://onco.cc/trials/checkmate-067/>, <https://onco.cc/trials/checkmate-238/>, <https://onco.cc/trials/checkmate-915/>, <https://onco.cc/trials/nadina/>, <https://onco.cc/trials/nivopostop/> ;
  onco:people <https://onco.cc/people/christian-blank/>, <https://onco.cc/people/john-haanen/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-metastasis-biology/>, <https://onco.cc/bottlenecks/b-tme-immunosuppression/>, <https://onco.cc/bottlenecks/b-toxicity-qol/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-dillekas-cancer-med/>, <https://onco.cc/key-papers/paper-hodi-ipilimumab-melanoma-nejm-2010/>, <https://onco.cc/key-papers/paper-nivolumab-melanoma-n-engl-j-med-2015/>, <https://onco.cc/key-papers/paper-keynote-006-pembrolizumab-ipilimumab-melanoma-nejm-2015/> .